Approved or advanced experimental MS therapies

2015 Review of Newly Approved Oncologic Therapies

Experimental therapies for psoriasis.

There is a high medical need for better therapies for psoriasis. Based on new insight into the pathophysiology of this frequent immune disease, a number of novel systemic immunomodulatory therapies are currently in clinical development. These include approaches targeting antigen presentation and costimulation, T cell activation and leukocyte adhesion, action of proinflammatory mediators, and mo...

Latest Approved Therapies for Metastatic Melanoma: What Comes Next?

Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, t...

The value of approved therapies for pulmonary arterial hypertension.

In this issue of the Journal, Macchia et al present the first meta-analysis of trials for pulmonary arterial hypertension (PAH). Their findings are startling, yet not surprising at the same time. Meta-analyses can be very helpful in strengthening the power of small intervention effects and in providing guidance for future clinical trials with respect to the population enrolled, appropriate end ...

Advanced Wound Care Therapies for